secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYNE Therapeutics Inc. (VYNE)
CIK:        0001566044
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001628280-25-023478
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VYNE Q1 net loss $8.6M; VYN202 psoriasis trial on clinical hold; repibresib vitiligo data due mid-2025
--------------------------------------------------------------------------------

- Cash $50.3M; net loss $8.6M ($0.20/sh) vs $6.2M in Q1 2024.
- R&D expenses $6.1M, up from $3.7M, driven by VYN202 and repibresib trials.
- Phase 1b psoriasis trial of VYN202 placed on clinical hold after testicular toxicity in dogs.
- Repibresib gel Phase 2b vitiligo top-line results expected mid-2025; fully enrolled.
- Revenue $0.2M from LEO Pharma royalty; cash runway into 2H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1566044/000162828025023478/0001628280-25-023478-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1566044/000162828025023478/mnlo-20250508.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-023478

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer